Nehal & Sons’ Post

🌟 Embrace the African Dream: Revolutionizing Pharma with Nehal and Sons! 💊🚀 Greetings, Africa! Are you primed for an extraordinary voyage into entrepreneurial discovery? Join forces with Nehal and Sons, alongside our esteemed consultant, Muhammad Wamiq, as we pave a new path in pharmaceutical innovation across Africa. 🌍✨ We're thrilled to unveil a myriad of premium business solutions crafted specifically for visionary minds in the pharmaceutical sector. At Nehal and Sons, we're committed to nurturing growth and innovation, propelling your pharmaceutical aspirations to unparalleled success in Africa's dynamic markets. With our extensive network of local distributors and robust channels, the gateway to market expansion and product penetration has never been more accessible. Whether you're introducing groundbreaking medications, innovative healthcare solutions, or cutting-edge medical devices, our tailored strategies are designed to catapult your pharmaceutical ventures to new heights. What Sets Us Apart? 🌟 1️⃣ Comprehensive Support: From conceptualization to commercialization, our holistic approach ensures every facet of your pharmaceutical venture is meticulously planned and executed for optimal success. 2️⃣ Local Expertise: Leveraging insights from trusted local partners, we decode the intricacies of the African pharmaceutical market, providing invaluable guidance to navigate regulatory landscapes and consumer preferences. 3️⃣ Scalable Triumph: Whether you're a budding startup or a seasoned pharmaceutical giant, our solutions are adaptable to your evolving needs, ensuring scalable growth and market dominance. 4️⃣ Sustainable Impact: Committed to ethical practices and responsible pharmaceutical manufacturing, we strive to make a lasting positive impact on healthcare accessibility and affordability across Africa. Africa beckons pharmaceutical pioneers like never before, offering a fertile ground for innovation and growth. Are you prepared to introduce life-changing pharmaceutical products and healthcare solutions to the African populace? Let us help craft compelling market entry strategies to captivate this burgeoning market. Join us as we embark on this transformative journey, revolutionizing pharmaceutical innovation and healthcare access across the African continent. Ready to make your mark with Nehal and Sons? Explore our suite of premium business solutions, meticulously designed to propel your pharmaceutical ventures to unparalleled success in Africa. To inquire or schedule an appointment, reach out to us at +92-346-302-999-3 #PharmaInnovation #AfricanMarketExpansion #HealthcareRevolution #NehalAndSons #MuhammadWamiqConsulting #PremiumSolutions #MarketPenetration #EntrepreneurialTriumph #PharmaIndustry #TransformativeHealthcare #SeizeTheOpportunity #PharmaCEOs #ManufacturersInPakistan #ManufacturersInDubai #PharmaLeadership #InvestInAfrica #BrandBuilding #PharmaMarketing #DistributionServices #BookAnAppointment

🌟 Seize the African Dream: Empowering Pharmaceutical Innovation with Nehal and Sons! 💊🚀 Hello, Africa! Are you prepared to embark on an extraordinary journey of entrepreneurial discovery? Join hands with Nehal and Sons, in collaboration with our esteemed consultant, Muhammad Wamiq, as we pave the way for revolutionary advancements in the pharmaceutical industry across the African continent. 🌍✨ We are thrilled to unveil a plethora of premium business solutions tailored explicitly for visionaries within the pharmaceutical sector. At Nehal and Sons, we are dedicated to fostering innovation and growth, propelling your pharmaceutical aspirations towards unparalleled success in the vibrant markets of Africa. Empowered by our extensive network of local distributors and robust channels, the path to market expansion and product penetration has never been more accessible. Whether you're introducing groundbreaking medications, innovative healthcare solutions, or pioneering medical devices, our bespoke strategies are crafted to propel your pharmaceutical ventures to new heights. Why Choose Us? 🌟 1️⃣ Comprehensive Guidance: From conceptualization to commercialization, our holistic approach ensures that every aspect of your pharmaceutical venture is meticulously planned and executed for optimal success. 2️⃣ Local Expertise: Leveraging the insights of our trusted local partners, we decipher the intricacies of the African pharmaceutical market, providing invaluable guidance to navigate regulatory landscapes and consumer preferences. 3️⃣ Scalable Success: Whether you're a burgeoning startup or an established pharmaceutical giant, our solutions are designed to adapt to your evolving needs, ensuring scalable growth and market dominance. Africa beckons pharmaceutical pioneers like never before, offering a fertile ground for innovation and growth. Let us assist you in crafting compelling market entry strategies to captivate this burgeoning market. Join us as we embark on a transformative journey, revolutionizing pharmaceutical innovation and healthcare access across the African continent. Ready to carve your mark with Nehal and Sons, alongside the expertise of Muhammad Wamiq? Explore our suite of premium business solutions, meticulously crafted to propel your pharmaceutical ventures towards unparalleled success in the African market. For inquiries or to explore partnership opportunities, connect with us at +92-346-302-999-3. Your journey to pharmaceutical excellence begins here! 💊📲 #PharmaceuticalInnovation #AfricanMarketExpansion #HealthcareRevolution #NehalAndSons #MuhammadWamiqConsulting #PremiumSolutions #MarketPenetration #EntrepreneurialTriumph #PharmaceuticalIndustry #TransformativeHealthcare #SeizeTheMoment #PharmaceuticalCEOs #ManufacturersInPakistan #ManufacturersInDubai #PharmaceuticalLeadership #UAEdistributors #GulfInvestors #InvestInAfrica #DistributorOpportunities

🇸🇮💡🔬 Swiss Pharmaceutical Giants investing in Slovenia: A Thriving Cutting-Edge Pharma and Research Hub   💊🌍 🚀Swissinfo journalists Céline Stegmüller, Jessica Davis Pluess,  Pauline TURUBAN wrote the article "Swiss pharma’s big bet on Slovenia" on investments of Novartis and Sandoz in Slovenia, which is emerging as a powerhouse in pharmaceuticals and research. The two Swiss pharmaceutical giants have invested more than CHF 3.5 billions in Slovenia, contributing in catalyzing Slovenia's evolution into a global player in drug production and research and at the same time making Slovenia an indispensable partner for these Swiss pharma giants. 🤝 🔍 The collaboration between Novartis and Sandoz  and Slovenia has thrived, with significant investments announced recently. In 2022, Novartis committed another $350 million, and Sandoz, now as an independent entity, pledged a historic $400 million for biosimilars production, marking the largest single foreign investment in Slovenia's history. The investments underscore Slovenia's crucial role in the global pharmaceutical landscape and its evolution from a production of generics to an innovation hub with cutting-edge research and development for complex biologics 🧬. 🇸🇮  Slovenian government plays an important role. Slovenian State Secretary for internationalization, entrepreneurship, development resources and tourism Matevž Frangež told SWI that Slovenia's strategic ambition is to evolve from a competent and reliable supplier to an innovation-driven developer of solutions and that the pharmaceutical sector is a key driver of this. He also emphasized that Slovenia has invested heavily in education, specifically scientific fields, in the last decade and offers various incentives for investors including tax deductions for innovation. Read the full article here: https://lnkd.in/e4mJZzfP #SloveniaOpportunities #Novartis  #Sandoz #Innovation #Research #Investment #Slovenia #Switzerland

The Biopharma UK/ Europe Opportunity: Strategic Partnering and M&A Considerations Typically, biopharma companies, as they grow from small to mid-size, focus their efforts on the US and their market of origin for commercial launch. As traction for their products and services grow, the next step is to expand into other geographies either organically or inorganically, through strategic partnering and M&A. For those non-European biopharmas, capturing opportunities in UK and Europe is often their next priority, given this combined geography accounts for over 20 per cent of the total global pharma market. The challenge with this geographic expansion is that UK/ Europe presents a complex and highly fragmented landscape: 31 markets within the European Union (EU), requiring European Medicines Agency (EMA) approval, as well as other markets with their own regulatory authorities, such as Switzerland with Swissmedic; also the MHRA in UK has developed its own standards to distinguish itself from EMA. There are also distinct healthcare systems and reimbursement processes for each market. Consequently, for many non-European life science firms, expanding their products and services in Europe is not straightforward. In our view, non-European biopharma players can tackle these challenges head-on as they expand into UK/ Europe markets: - Establish market credibility: Lack of brand recognition among target companies can make it challenging to secure a deal. In a horizon scan for a Japanese CRO client, one of the identified targets was unable to relate to potential outbound opportunities from a minority investment deal; brand building and market shaping efforts are critical prior to anticipated entry. - Test your value proposition with potential customers and partners in Europe to understand positioning vis-à-vis the competition prior to entry. Validating the value proposition through confidential external interviews, conducted on your behalf, prior to potential target discussions can be useful to deliver optimal selling messages to potential targets. - Consider investing in pre-deal diligence: Deal cycles are often shorter in promising opportunity areas with higher levels of sector consolidation. Heightened investor interest could mean that target assets are approached quickly to avoid opportunities being missed. An investment in pre-deal diligence can help pre-qualify investment goals, supported by an initial revenue forecast and valuation of the target, prior to target approach. Many investor and life science business development teams are attempting to develop go-to-market strategies for UK/ Europe expansion given the size of the opportunities. An external, independent view on European market dynamics, and value creation opportunities and targets to pursue, will help them to secure sustainable partnering outcomes. #life sciences deals #strategic partnering and M&A #EU market entry #life sciences M&A

We have been closely monitoring the evolving landscape of Thailand's pharmaceutical industry in the aftermath of the COVID-19 pandemic. The global healthcare crisis has underscored the importance of resilience and innovation, paving the way for new opportunities in the pharmaceutical sector in Thailand. Thailand's national pharmaceutical industry has long been recognized for its strength and capabilities in producing high-quality medical products. However, as we navigate the post-COVID era, the industry stands at a crucial juncture where additional support from investors can propel it towards even greater success. Investing in Thailand's pharmaceutical industry is not just about financial gains; it is about sharing expertise, knowledge, and fostering a collaborative mindset. Foreign investments bring more than just monetary value; they bring invaluable know-how, technical expertise, and a fresh perspective to the table. Embracing foreign investors can lead to the transfer of cutting-edge technologies, best practices, and strategic approaches that can enhance the competitiveness and sustainability of the local pharmaceutical sector. By welcoming investors or considering investments in Thailand, stakeholders have the opportunity to contribute to the growth and transformation of the pharmaceutical industry. The influx of investments can catalyze the development of innovative healthcare solutions, boost manufacturing capabilities, and improve access to essential medications for the Thai population. Moreover, foreign investments can serve as catalysts for change, driving the adoption of new technologies, fostering a culture of continuous improvement, and promoting a global mindset within the industry. The exchange of knowledge and experience between local and foreign stakeholders can fuel creativity, drive innovation, and ultimately elevate the standards of the pharmaceutical sector in Thailand. In conclusion, the time is ripe to recognize the immense potential of Thailand's pharmaceutical industry and to leverage the expertise and resources that foreign investors bring to the table. Embracing investments in the pharmaceutical sector is not just a financial decision; it is a strategic move towards building a more resilient, innovative, and competitive healthcare ecosystem in Thailand. #InvestmentOpportunities #ThailandPharmaceuticalIndustry #PostCOVIDInvestme #ForeignInvestors #KnowledgeTransfer #InnovationInHealthcare #GlobalMindset #SustainableGrowth #HealthcareTransformation #InvestInThailand

Increased spending on public health in China is likely to boost pharmaceutical companies like Dr. Reddy’s Laboratories Ltd, which operates via a joint venture and a wholly-owned subsidiary in the Dragon Nation. With over 20 years of experience in China, the company is gearing up to tap into the opportunity with a more focused approach. The company’s Chief Executive Officer for Branded Markets (India and Emerging Markets), M.V. Ramana, shared his thoughts with Informist on market opportunities, regulatory challenges, product filings, and the launch pipeline. Read more at Informist: https://lnkd.in/g6Ygcb5S #InformistExclusives #PharmaceuticalIndustry #ChinaMarket #HealthcareInvestment #DrReddys #MarketOpportunities 

AstraZeneca is strategically building a separate supply chain for China in the Chinese city of Qingdao to mitigate potential disruptions caused by escalating US-China tensions. CEO Pascal Soriot emphasised the importance of Chinese drug sales and innovation in achieving the company's ambitious $80bn revenue target by 2030. Having done a number of investigative projects for international clients in the pharmaceutical and healthcare industries in the past two years, we can see that the Chinese market is crucial for multinational corporations in these fields due to several key reasons. Firstly, China represents a significant growth opportunity for the said industries, with a rapidly expanding healthcare sector and increasing demand for innovative medicines. By focusing on China, multinational pharmaceutical and healthcare firms can tap into a large and growing patient population, driving sales and revenue growth. Additionally, China has become a hub for healthcare innovation in recent years, offering global corporations access to cutting-edge research and development opportunities. A good example is AstraZeneca's $1.2bn acquisition of Gracell Biotechnologies, a Chinese maker of advanced cancer therapies known as Car-T cell therapy, in December last year. Establishing a dedicated supply chain in China will allow companies like AstraZeneca to strengthen their presence in the country, enhance its competitiveness, and navigate potential disruptions in the global market, particularly amid rising US-China tensions. https://lnkd.in/e9bD8V3v #astrazeneca #pharmaceutical #supplychainriskmanagement #geopolitics #uschinatradetensions #multinational #riskassessment #healthcare #researchanddevelopment #innovation

Italy's pharmaceutical sector is one of the largest in Europe, with a total industry value of over €34 billion. Italy is also home to over 700 #biotech companies, with 75% focusing on healthcare-related research. The Italian biotech sector is particularly strong in areas such as #oncology, #rare #diseases, and #immunotherapy, providing excellent collaboration opportunities for foreign companies seeking to leverage Italy’s expertise in these fields. Italy’s strategic location within Europe and its well-established network of life sciences clusters make it an ideal entry point for #Asian biopharma companies looking to expand in the EU. However, entering the Italian market requires a strong understanding of local regulations, as well as partnerships with key stakeholders. At Zeta Health Solutions, we offer market entry support tailored to biopharma companies, helping you navigate requirements, identify key partners, and establish a strong presence in Italy and beyond. DM us to learn more about how we can support your expansion into Italy. What opportunities do you see in the Italian pharma industry? Let’s chat in the comments! #Asia #AsiaPacific #Biotech #Pharma #Foodsupplements #Europe #PharmaItaly #MarketEntry #BiotechGrowth #PharmaEurope #India #China #Philippines #USA #Canada #Thailand #Australia #Japan

After Novartis' exit, Indian Sun Pharma’s subsidiary Sun Pharma Bangladesh is the only remaining foreign drug maker in Bangladesh that has a local plant here. After the exits of western drug multinationals GlaxoSmithKline, Nuvista and Sanofi, now the Switzerland-based Novartis AG has signed an agreement to sell its entire 60% stake at Novartis Bangladesh Limited (NBL) to homegrown Radiant Pharmaceuticals. From my feel of the global manufacturing network, I don't think the reason why drug companies are leaving Bangladesh has anything to do with Bangladesh. There are larger forces at play and global markets have changed where drug companies are now forced to consolidate factories. At the top of all of all of this is a international trade war driven by nationalist interests. The Western nations have retreated on a global strategy and have been making it more difficult to export and import goods. Some of this is generally good; changes in local taxes have made the US and Ireland more attractive locations to manufacture drugs. Others are bad; increased incentives to do forced tech transfers and increased tariffs on Chinese goods have made the cost of operations more expensive. There are a lot of pricing pressure on drug companies too. Reduced sales of new drugs and increased costs to maintain global companies have lead the big pharma companies to consolidate operations back into the Western markets and to focus on Western diseases while handing off third world drug development to an emerging Chinese and Indian drug development industry. We have seen a lot of big pharma companies closing down overseas facilities and returning back to their US/European locations. This also isn't unique to biopharma, companies in general have been moving back as the US and the EU become more isolated. Not of all of this necessarily bad. There is a general reduction in foreign investment but many of these factories stay open as they change hands to another contract manufacturer. Likely these sites will stay open but under a different name. Bangladesh will still hold onto its pharmaceutical industry. A scenario for Vietnam???

It was a real pleasure to moderate the Panel on ADDRESSING PANDEMICS THROUGH PARTNERSHIPS in the Prix Galien Awards today in New Delhi. The distinguished Panel included Thomas Cueni, Director General, IFPMA Sudarshan Jain, International Generic and Biosimilar medicines Association (IGBA), Rajinder Suri, CEO, Developing Countries Vaccines Manufacturers (DCVMN), Vignesh Shivnath, Director, Business Development & Alliance Management. Dr. Reddy’s Lab, and Jasdeep Singh Sood, Senior Vice President Jubilant Pharma & President Generic. The unprecedented nature and scale of the #pandemic affirmed the importance of the following: FIRST - that the #innovation ecosystem was critical for finding new cures - a large number of projects were initiated in a remarkably short time during the initial months of the pandemics indicating innovation and risk taking. In vaccines, there were 462 in pre-clinical developments and 5 made it to the market AND for therapeutics, 18 out of 900 made it to the market. 75% of this investment has been made at risk by the private sector, both innovative and generic pharmaceutical companies. SECOND – it put the spotlight on partnerships, covering all parts of the value chain  – partnerships between established bio-pharmaceutical companies, small biotech companies, research and academic institutions; supply chain arrangements; and downstream manufacturing agreements. The Airfinity data further shows that over 450 #voluntarylicenses – 177 in therapeutics alone - are in place to support the global supply of COVID-19 vaccines and treatments. The top VL locations were India, China, South Africa, South Korea, Bangladesh and Pakistan. These collaborations were voluntary, varied and dynamic, requiring close working relationships and trust amongst partners. THIRD - Most of the #manufacturing #partnerships for therapeutics and vaccines were signed in parallel or prior to companies seeking regulatory approval authorization, or were announced within days of approval. The innovator company helped partnering companies in the in-country regulatory approval processes. This puts the focus on important discussions around #regulatory #convergence, securing #supplychains, removing #exportrestrictions and #trade facilitation. Thank you Komal Kalha and Ana-Maria N. for putting this panel together. And thank you Bruno Cohen and the The Galien Foundation. Corporate Law Group